BrainStorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; Alzheimer's disease; and other neurodegenerative diseases. NurOwn®, Co.'s proprietary platform, utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The BCLI stock yearly return is shown above.
The yearly return on the BCLI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BCLI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|